Mode
Text Size
Log in / Sign up
N/A Completed N=200 Randomized Single-blind Supportive Care

Hatha Yoga in Improving Physical Activity, Inflammation, Fatigue, and Distress in Breast Cancer Survivors

Source: ClinicalTrials.gov NCT00486525 ↗
Enrolled (actual)
200
Serious AEs
0.0%
Results posted
Apr 2014
Primary outcomePrimary: Stimulated ln (TNF-a) — 8.31; 8.39; 8.31; 8.44 ln (pg/mL) — p=0.20

Summary

RATIONALE: Yoga may improve inflammation, fatigue, and depression in female breast cancer survivors. PURPOSE: This randomized clinical trial is studying how well Hatha yoga works in improving physical activity, inflammation, fatigue, and distress in female breast cancer survivors.

Outcome Measures

OutcomeResultp-value
PRIMARY
Stimulated ln (TNF-a)
8.31; 8.39; 8.31; 8.44 0.20
PRIMARY
Stimulated ln (IL-6)
9.68; 9.76; 9.69; 9.85 0.2
PRIMARY
Stimulated ln (IL-1b)
8.31; 8.42; 8.32; 8.55 0.33
PRIMARY
MFSI-SF Fatigue
6.1; 10.3; 5.4; 12.4 0.058
PRIMARY
Vitality, SF-36
58.7; 52.3; 58.1; 51.6 0.01 sig
PRIMARY
CES-D
8.1; 9.2; 8.5; 9.7 0.28

Eligibility Criteria

DISEASE CHARACTERISTICS:

  • Stage 0-IIIA breast cancer survivor
  • Completed cancer treatment within the past 36 months (except for tamoxifen/aromatase inhibitors)
  • At least 2 months since prior surgery, adjuvant therapy, or radiotherapy, whichever occurred last
  • Women who are not currently practicing yoga and have not participated in any of the following activities:
  • Meditation, tai chi, or related activities
  • Yoga or tai chi within the past 6 months
  • Had classes for or practiced yoga for more than 3 months
  • Women who typically engage in a total of 5 or more hours of vigorous physical activity per week are not eligible
  • No inflammatory breast cancer

PATIENT CHARACTERISTICS:

Inclusion criteria

  • Hemoglobin ≥ 10 g/dL (patients with a hemoglobin of < 10 g/dL may be retested in 6 weeks after treatment of anemia and allowed to participate in study if blood counts recovered)
  • Physically able to fully participate in yoga intervention

Exclusion criteria

  • Inability to comfortably get up and down from the floor 2-3 times in a session
  • Breathing problems requiring use of oxygen
  • Problems walking without a cane or walker assistance
  • Prior knee or hip replacement with limited movement in the joint
  • Inability to comfortably lie on the stomach
  • Alcohol, or drug abuse
  • Diagnosis of any of the following conditions:
  • Diabetes
  • Chronic obstructive pulmonary disease
  • Uncontrolled hypertension
  • Evidence of liver or kidney failure
  • Symptomatic ischemic heart disease
  • Significant visual or auditory problems
  • Mental disorder or cognitive impairment
  • Notable serious cardiovascular history (e.g., prior life-threatening abnormal heart rhythms)
  • Other medical conditions involving the immune system such as autoimmune and/or inflammatory diseases including rheumatoid arthritis and ulcerative colitis
  • History of breast or any other cancer, except basal or squamous cell skin cancer

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • No regular use of medications with major immunological consequences (e.g., steroids)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00486525). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search